RDY Positive Sentiment Score: 70/100
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co
Friday, August 4, 2023 1 min read
Key Takeaway: Dr. Reddy's Laboratories has reported the conclusion of a USFDA inspection at its API manufacturing facility in Bollaram, Hyderabad. The inspection has been classified as Voluntary Action Indicated (VAI), indicating that no immediate actions or sanctions are required. The Establishment Inspection Report (EIR) has confirmed that the inspection is officially closed, affirming compliance with regulatory standards. This development reflects positively on the company's operational standing.
Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code:
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Further to our intimation dated May 5, 2023, on the
inspection conducted by the United States Food & Drug Administration (USFDA) at our API manufacturing facility in Bollaram, Hyderabad
(CTO 1), we wish to inform you that the Company has received the Establishment Inspection Report (EIR). The Agency has classified the
inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed" under 21 CFR 20.64(d)(3).
Kindly take the above on your record.
For Dr. Reddy's Laboratories Limited
| K Randhir Singh | |
| Company Secretary, Compliance Officer and Head-CSR | |